March 20, 2020
The presence of a foreign tablet in a bottle of carbidopa and levodopa tablets has prompted Mayne Pharma Inc. to recall the remaining bottles in the lot, according to the March 18, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects carbidopa and levodopa tablets, 25 mg/250 mg, 100-count bottles (NDC 51862-858-01), from lot FG11514 (Exp. 5/21). The bottles were distributed throughout the United States.
Mayne Pharma voluntarily initiated the recall March 2, 2020. At press time, the FDA had not yet issued a recall classification.
Carbidopa and levodopa tablets are available with a prescription to treat symptoms of Parkinson disease.